Clinical trials: Stage II Pancreatic Cancer
Pancreatic Cancer
A Trial of Chemo & Radiation Therapy for Pancreatic Cancer
This is an open-label, non-randomized, combination study of cetuximab, gemcitabine, 5-FU, and external beam radiotherapy in patients with locally advanced, non-metastatic pancreatic cancer.
- Trial name
- NCT00424827
- Testing
- Gemcitabine/Fluorouracil with External Beam Radiation
- Volunteers
- 11 people
- Sponsor
- University of Massachusetts, Worcester
Cancer
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill…
- Trial name
- NCT00002854
- Testing
- filgrastim, carboplatin, cisplatin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- City of Hope Medical Center
Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with unresectable, locally advanced, or metastatic solid tumors…
- Conditions
- Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT07623642
- Testing
- GV20-0251, anti-PD-1 monoclonal antibodies
- Where
- 2 sites in China
- Volunteers
- 227 people
- Sponsor
- GV20 Therapeutics
Pancreatic Cancer
Biomarkers in Plasma Specimens From Patients Treated on Study CALGB-80303
RATIONALE: Studying plasma samples from patients with pancreatic cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT01664169
- Testing
- laboratory biomarker analysis
- Volunteers
- 307 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Metastatic Pancreatic Cancer
Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer
This is a single arm, open-label Phase II clinical trial to Evaluate the Efficacy and Safety of the Combination of Nab-paclitaxel and Gemcitabine in Treating Patients with metastatic pancreatic cancer.
- Trial name
- NCT03929094
- Testing
- Paclitaxel for Injection（Albumin Bound）, Gemcitabine
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Fudan University
Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body…
- Conditions
- Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8
- Trial name
- NCT06906562
- Testing
- Pemigatinib, Computed Tomography (CT), Magnetic Resonance Imaging
- Where
- 109 sites in United States
- Volunteers
- 40 people
- Sponsor
- Sameek Roychowdhury
Neuroendocrine Tumors
Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET
Peptide Receptor Radionuclide Therapy (PRRT) is based on specific somatostatin receptor targeting with radiolabelled analogues 90Y-DOTATOC and 177Lu-DOTATATE.
- Trial name
- NeoLuPaNET (NCT04385992)
- Testing
- 177Lu-Dotatate
- Where
- Italy
- Volunteers
- 31 people
- Sponsor
- IRCCS San Raffaele
Pancreatic Cancer
Fluorouracil, External-Beam Radiation Therapy, and Gemcitabine With or Without Brachytherapy Using Phosphorus P32 in Treating Patients With Locally or Regionally Advanced Unresectable Adenocarcinoma of the Pancreas
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00079365
- Testing
- fluorouracil, gemcitabine hydrochloride, brachytherapy
- Where
- United States
- Sponsor
- University of South Florida
Esophageal Neoplasms, Hepatocellular Carcinoma
A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies
To determine the rate of response and the duration of the response following therapy with Aroplatinin patients with advanced solid malignancies.
- Conditions
- Esophageal Neoplasms, Hepatocellular Carcinoma, Colorectal Neoplasms, Ovarian Neoplasms
- Trial name
- NCT00057395
- Testing
- Aroplatin (Liposomal NDDP, L-NDDP)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Aronex Pharmaceuticals
Pancreatic Cancer, RAS Mutations or Amplifications
A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer
This study aims to evaluate the safety, tolerability, and efficacy of HRS-2329 in combination with other anti-tumor therapies in participants with advanced pancreatic cancer harboring RAS mutations or amplifications.
- Trial name
- NCT07736612
- Testing
- HRS-2329 Tablet, Nimotuzumab, HS-20093
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Zhejiang University
Cancer of Pancreas
A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas
A randomized phase II study evaluating maintenance therapy after first line induction chemotherapy in metastatic cancer pancreas.
- Trial name
- NCT05566743
- Testing
- Capecitabine, follow up
- Where
- 3 sites in Egypt
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Menoufia University
Anal Cancer, Carcinoma of the Appendix
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
RATIONALE: Palonosetron hydrochloride may prevent nausea and vomiting caused by radiation therapy. It is not yet known whether palonosetron hydrochloride is more effective than a placebo in preventing nausea and vomiting.
- Conditions
- Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00903396
- Testing
- palonosetron hydrochloride
- Where
- 69 sites in United States
- Volunteers
- 7 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pancreatic Cancer
Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer
To determine the response rate and survival of gemcitabine and pazopanib in patients with metastatic pancreatic cancer.
- Trial name
- NCT01080248
- Testing
- Gemcitabine, Pazopanib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Washington University School of Medicine
Pancreatic Cancer
Gemcitabine or Gemcitabine and Cisplatin in the Treatment of Advanced Pancreatic Cancer
The purpose of this study is to evaluate the impact of the addition of cisplatin to gemcitabine in the treatment of patients with inoperable advanced pancreatic cancer.
- Trial name
- GIP-1 (NCT00813696)
- Testing
- gemcitabine, cisplatin
- Where
- 45 sites in Italy
- Volunteers
- 400 people
- Sponsor
- Istituti Tumori Giovanni Paolo II
Pancreatic Cancer
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
This study is a multicenter, open-label, single-arm, phase Ib/II clinical study comprising two phases: dose confirmation phase and dose expansion phase.
- Trial name
- NCT05827796
- Testing
- IN10018, Albumin-Bound Paclitaxel, Gemcitabine
- Where
- China
- Volunteers
- 70 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Pancreatic Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells.
- Trial name
- NCT00026403
- Testing
- cisplatin, gemcitabine hydrochloride, radiation therapy
- Where
- 26 sites in United States, Canada
- Volunteers
- 48 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pancreatic Cancer
A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation
This is a phase 2 study. All subjects are patients with locally advanced unresectable or metastatic pancreatic cancer harboring KRAS G12D mutation who have received at least one prior line of systemic therapy.
- Trial name
- NCT07784374
- Testing
- GFH375, GFH276, GFS202A
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Advanced Pancreatic Cancer
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer
This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced pancreatic cancer.
- Trial name
- NCT03509298
- Testing
- Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Pancreatic Cancer, cryotherapy
- Where
- China
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Pancreatic Cancer
Radiotherapy With Chemotherapy as Neoadjuvant Therapy of Resectable and Borderline Resectable Pancreas Cancer
The purpose of this study is to determine safety and to obtain preliminary estimates of the rate of major pathologic response of neoadjuvant accelerated fraction, standard dose radiation given with chemotherapy in patients with…
- Trial name
- NCT01333332
- Testing
- Capecitabine, Standard Dose Acclerated Fraction Radiotherapy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Virginia
Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
This is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless…
- Trial name
- DPT01 (NCT04639219)
- Testing
- Trastuzumab deruxtecan
- Where
- 30 sites in United States, Belgium and 7 more
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.